CareDx, Inc.
For the period ended Sep 30, 2026. Filed Oct 29, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Oct 29, 2026
CDNA$80.77-4.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenue: | ||||
| Testing services revenue | $119,191 | $72,168 | $310,516 | $196,122 |
| Product revenue | — | 12,478 | 23,137 | 35,121 |
| Patient and digital solutions revenue | 20,171 | 15,409 | 55,357 | 40,176 |
| Total revenue | 139,362 | 100,055 | 389,010 | 271,419 |
| Operating expenses: | ||||
| Cost of testing services | 24,683 | 14,705 | 57,698 | 45,224 |
| Cost of product | — | 5,629 | 9,176 | 16,196 |
| Cost of patient and digital solutions | 15,604 | 10,320 | 42,008 | 26,307 |
| Research and development | 21,324 | 16,769 | 65,116 | 52,123 |
| Sales and marketing | 31,650 | 24,449 | 95,464 | 71,719 |
| General and administrative | 37,989 | 28,429 | 109,381 | 78,881 |
| Gain on sale of lab products business | — | — | (112,966) | — |
| Litigation settlement expense | — | — | 600 | 5,710 |
| Total operating expenses | 131,250 | 100,301 | 266,477 | 296,160 |
| Income (loss) from operations | 8,112 | (246) | 122,533 | (24,741) |
| Other income: | ||||
| Interest income, net | 2,208 | 2,013 | 5,852 | 7,161 |
| Other income (expense), net | 372 | (107) | (398) | 260 |
| Total other income | 2,580 | 1,906 | 5,454 | 7,421 |
| Income (loss) before income taxes | 10,692 | 1,660 | 127,987 | (17,320) |
| Income tax benefit | 8,600 | 15 | 4,750 | 74 |
| Net income (loss) | $19,292 | $1,675 | $132,737 | $(17,246) |
| Net income (loss) per share (Note 3): | ||||
| Basic | $0.37 | $0.03 | $2.57 | $(0.32) |
| Diluted | $0.35 | $0.03 | $2.45 | $(0.32) |
| Weighted-average shares used to compute net income (loss) per share: | ||||
| Basic | 52,116,051 | 52,507,582 | 51,582,605 | 54,016,446 |
| Diluted | 54,984,989 | 53,736,790 | 54,277,326 | 54,016,446 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.